<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002148</url>
  </required_header>
  <id_info>
    <org_study_id>242A</org_study_id>
    <secondary_id>02-D94</secondary_id>
    <nct_id>NCT00002148</nct_id>
  </id_info>
  <brief_title>Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia</brief_title>
  <official_title>Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the tolerability and safety of OPC-14117. To evaluate effects of OPC-14117 on
      cognitive function, quality of life, and activities of daily living.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive OPC-14117 or placebo bid for 12 weeks, followed by 12 weeks of open label
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Cognitive Disorders</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC 14117</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV seropositivity.

          -  Cognitive impairment.

        Prior Medication:

        Allowed:

          -  Prior OPC-14117 other than on the current study.

          -  Antiretroviral therapy if stable for 6 weeks prior to study entry (12 weeks for
             stavudine).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Current opportunistic CNS infection (i.e., toxoplasmosis or cryptococcal meningitis).

          -  Severe pre-morbid psychiatric illness including schizophrenia and major depression
             that would interfere with protocol compliance.

          -  CNS neoplasms.

          -  Any other clinically significant condition or laboratory abnormality that would
             interfere with ability to participate on study.

          -  Current participation in other drug studies.

        Patients with the following prior conditions are excluded:

          -  Past history of opportunistic CNS infection (i.e., toxoplasmosis or cryptococcal
             meningitis).

          -  History of chronic neurological disorders such as serious head injury, documented
             stroke, multiple sclerosis, uncontrolled epilepsy, Tourette's syndrome, and other
             neurodegenerative processes such as Huntington's disease.

          -  History of adverse reaction / allergy to OPC-14117.

          -  Prior participation on this study.

        Prior Medication:

        Excluded:

          -  Other investigational drugs within the past 30 days. Alcoholism within past 6 months
             (more than 2 drinks daily).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212876965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Med Ctr</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology. 1997 Jul;49(1):142-6.</citation>
    <PMID>9222182</PMID>
  </reference>
  <verification_date>March 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Cognition Disorders</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Free Radical Scavengers</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>OPC 14117</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>AIDS Dementia Complex</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

